Drug-Coated Stent Pivotal Study Will Show Improved TVR Rates, Cook Says
This article was originally published in The Gray Sheet
Executive Summary
Cook's 1,200-patient, six-center U.S. pivotal trial (PATENCY) evaluating the Logic PTX paclitaxel-coated stent in treating de novo lesions should complete enrollment in early 2002.